Cangrelor to Clopidogrel or Prasugrel Transition Study
Condition: Coronary Artery Disease (CAD)
MeSH terms: Coronary Artery Disease; Myocardial Ischemia; Coronary Disease
Intervention: Cangrelor; Clopidogrel; Prasugrel
Intervention description: Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.; Clopidogrel 600 mg single oral dose; Prasugrel 60 mg single oral dose
Intervention MeSH terms: Clopidogrel; Prasugrel Hydrochloride; Cangrelor
Phase: Phase 2
Study type: Interventional
Primary purpose: Basic Science
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 15.0
Sex: All
Minimum age: 18 Years
Maximum age: 74 Years
Healthy volunteers: No
Keywords: CAD

Summary:

      There are two separate objectives in this study:

        1. To demonstrate the pharmacodynamic (PD) profile when participants treated with cangrelor
           are switched to oral prasugrel 60 mg administered 30 minutes (min) after cangrelor
           infusion is discontinued

        2. To demonstrate the PD profile when participants treated with cangrelor are switched to
           oral clopidogrel 600 mg administered during or immediately after cangrelor infusion.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Greater than or equal to 18 and less than 75 years of age, of either sex, and of any
             race.

          2. Stable CAD defined by the following criteria:

               1. Previous myocardial infarction defined by admission to the hospital with
                  elevation of markers of injury or the presence of pathologic Q-waves on at least
                  2 contiguous electrocardiogram (ECG) leads.

                  or

               2. Previous revascularization by percutaneous coronary intervention or coronary
                  artery bypass graft, and

               3. Treatment with aspirin 81 mg daily.

        Exclusion Criteria:

          1. Known intolerance or contraindication to cangrelor or prasugrel, or any ingredients of
             the respective formulation.

          2. Any antiplatelet (other than aspirin) or anticoagulant medication within the previous
             30 days.

          3. Acute coronary syndrome within the previous 12 months.

          4. History of bleeding diathesis or known coagulopathy such as; impaired hemostasis;
             known international normalized ratio (INR) >1.5; past or present bleeding disorder
             (including congenital bleeding disorders, such as, von Willebrand's disease or
             hemophilia), acquired bleeding disorders, and unexplained clinically significant
             bleeding disorders; thrombocytopenia (platelet count less than 100,000/microliter
             [µL]), or history of thrombocytopenia or neutropenia associated with clopidogrel.

          5. Anemia (for example, hematocrit less than 35%).

          6. Prior stroke (any type), prior cerebral arteriovenous malformation or intracranial
             aneurysm; recent (<1 month) trauma or major surgery (including bypass surgery).

          7. Known or suspected pregnancy, or lactating females.

          8. Known severe renal insufficiency (glomerular filtration rate less than 30 milliliter
             [mL]/min).

          9. Inability to provide informed consent.

         10. Moderate or severe hepatic impairment as per Investigator's discretion (elevation of
             liver function tests).

         11. Inability to swallow oral medication at time of randomization.

         12. Any clinically significant disease or condition affecting a major organ system,
             including but not limited to gastrointestinal, renal, hepatic, endocrinologic,
             broncho-pulmonary, neurological, or metabolic disease.

         13. Any surgical or medical condition which, in the judgment of the Investigator, might
             interfere with the pharmacokinetics, distribution, metabolism, or excretion of the
             study drug (if applicable).

         14. Treatment with other investigational medicinal products or devices within 30 days or 5
             half-lives, whichever is longer, prior to the administration of the drug, or planned
             use of investigational medicinal products or devices.

         15. Participants who, for any reason, are deemed by the Investigator to be inappropriate
             for this study, including participants who are unable to communicate or to cooperate
             with the Investigator.

         16. Participant is the Investigator or his/her deputy, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the study.

         17. Active pathological bleeding, or a history of transient ischemic attack.